newsfilter
← Earnings
Earnings Releases·

Dogwood Therapeutics — Third Quarter 2026 Earnings Summary

Dogwood Therapeutics completed its Phase 2b trial for Halneuron in treating chemotherapy-induced neuropathy, with top-line results expected in November 2026. The company secured a $5 million private placement from Sealbond Limited to fund Phase 3 preparations and general operations, extending its cash runway through the first quarter of 2027. For the third quarter of 2026, the company reported $0.1 million in licensing revenue and a net loss of $4.9 million, a significant improvement from the $15.7 million loss recorded in the same period of 2025.

Company
DOGWOOD THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology